WEGOVY

[anonymous]

Unfortunately, there is no way to separate GLP1 effects on pancreas and effects on gastric emptying. Slowed gastric emptying causes weight loss. My question is will artificially causing pancreas to produce and store insulin with mega doses of synthetic long acting GLP1 cause any problems in otherwise healthy overweight patients vs. placebo? GLP1s have been studied since the 1980’s with diabetic patients. Diabetics have increased risk of pancreatitis. How will mega doses of long acting GLP1 compare with millions of otherwise healthy over weight patients? Medication control vs healthy placebo?

All diabetics have increased risk of pancreatitis. Previous GLP1 studies may have not been large enough to show true difference between diabetic medication control vs diabetic placebo. Unfortunately, there is no way to separate GLP1 effects of gastric emptying for weight loss and effects on pancreas. Natural GLP1 lasts for minutes. Now that mega doses of long acting laboratory GLP1 is used on otherwise heathy patients, how will pancreatitis look in medication heathy control compared to healthy placebo for pancreatitis? Will increased pancreatitis lead to pancreatic cancer? All this for cosmetic weight loss?

 

[anonymous]

Unfortunately, there is no way to separate GLP1 effects on pancreas and effects on gastric emptying. Slowed gastric emptying causes weight loss. My question is will artificially causing pancreas to produce and store insulin with mega doses of synthetic long acting GLP1 cause any problems in otherwise healthy overweight patients vs. placebo? GLP1s have been studied since the 1980’s with diabetic patients. Diabetics have increased risk of pancreatitis. How will mega doses of long acting GLP1 compare with millions of otherwise healthy over weight patients? Medication control vs healthy placebo?

I guess you better conduct a few multi billion dollar studies to evaluate these outcomes.

Oh wait.

 

[anonymous]

I guess you better conduct a few multi billion dollar studies to evaluate these outcomes.

Oh wait.

With these unnatural long acting GLP1s used for weight loss, doctors will report pancreatitis and pancreatic cancer. Unfortunately, there is no way to separate slowed gastric emptying effects and effects on pancreas with these drugs. Novo and Lilly will have”deep pockets” for lawyers to have field day. Share owners will suffer and employees will be fired.

 

[anonymous]

With these unnatural long acting GLP1s used for weight loss, doctors will report pancreatitis and pancreatic cancer. Unfortunately, there is no way to separate slowed gastric emptying effects and effects on pancreas with these drugs. Novo and Lilly will have”deep pockets” for lawyers to have field day. Share owners will suffer and employees will be fired.

Senior management will cash stock options. Many employees will be fired. Does anyone care about patients?

 

[anonymous]

Senior management will cash stock options. Many employees will be fired. Does anyone care about patients?

This is going to be another blow on the pharma industry as a whole. Similar to companies pushing pain medications and causing opioid crisis. A few get very rich, while patients, society, shareholders, employees all suffer. No one will believe benefit of temporary weight loss is worth risk of pancreatitis and likely pancreatic cancer. After millions of years of evolution, natural GLP1 lasts for minutes. We will all see the experiment of laboratory chemists making artificial GLP1 that lasts for weeks. Now use mega doses and we will all see Frankenstein’s creation!!!

 

[anonymous]

I know a diabetes specialist at a world renowned cancer center who avoids any medicine that stimulates the pancreas. Why artificially stimulate pancreas with synthetic mega doses for temporary weight loss? How will medicated control arms compare to otherwise healthly placebo? Millions of patients will take these medications. I hope lawyers get ready.

If there is a risk of pancreatitis then why would they put diabetics in the placebo controlled group? Your statement on that doesn’t make sense. I get that artificially stimulating the pancreas can’t be good long term.

 

[anonymous]

“If there is a risk of pancreatitis then why would they put diabetics in the placebo controlled group? Your statement on that doesn’t make sense. I get that artificially stimulating the pancreas can’t be good long term.”

Diabetic studies have to have similar Diabetics in both Medicine Control and Placebo groups. Because all diabetics have increased risk of pancreatitis, these diabetic studies may have not been large enough and have sufficient Statistical power to show true pancreatitis caused by synthetic GLP1s in diabetes.

The obesity population is different. How will artificially stimulating healthy pancreas compare to otherwise healthy obese placebo group having no increased incidence of pancreatitis?

Pancreatitis can lead to pancreatic cancer. Is it worth this risk for cosmetic weight loss?

 

[anonymous]

“If there is a risk of pancreatitis then why would they put diabetics in the placebo controlled group? Your statement on that doesn’t make sense. I get that artificially stimulating the pancreas can’t be good long term.”

Diabetic studies have to have similar Diabetics in both Medicine Control and Placebo groups. Because all diabetics have increased risk of pancreatitis, these diabetic studies may have not been large enough and have sufficient Statistical power to show true pancreatitis caused by synthetic GLP1s in diabetes.

The obesity population is different. How will artificially stimulating healthy pancreas compare to otherwise healthy obese placebo group having no increased incidence of pancreatitis?

Pancreatitis can lead to pancreatic cancer. Is it worth this risk for cosmetic weight loss?

If these chemistry laboratory produced long acting GLP1s cause pancreatitis and pancreatic cancer in healthy people to achieve weight loss, this is going to be another blow to whole pharma Industry. The executives cash stock options and many employees are fired. Very similar to what happen in opioid crisis a few years ago. Lawyers will get rich. Patients, institutions, and employees suffer.

 

[anonymous]

If these chemistry laboratory produced long acting GLP1s cause pancreatitis and pancreatic cancer in healthy people to achieve weight loss, this is going to be another blow to whole pharma Industry. The executives cash stock options and many employees are fired. Very similar to what happen in opioid crisis a few years ago. Lawyers will get rich. Patients, institutions, and employees suffer.

After millions of years of evolution, body produced GLP1 lasts for minutes. Does it make since to use mega doses of chemistry laboratory synthetic GLP1 engineered to last weeks for temporary weight loss? Does anyone care about patients or is stock price the main consideration? Trust me, this is going to end very ugly for almost everyone. I few, however, will get rich. GLP1 has been studied since the 1980’s. Wall Street acts like this is new and exciting.